COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 18
SponsorUniversity Hospital, Akershus
About this trial
Prospective cohort study of COVID-19 infection among children in Norway.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
Children seeking hospital care i Norway
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
350 Participants
are grouped into 2 trial groupsGroup A: Sars-CoV-2 positive
Group B: SARS-CoV-2 negative
Trial outcomes
Primary outcomes
1
Risk Factors for severe infection
Identify comorbidities predisposing for severe infection
Time frame
20302
Immunulogical mechanisms
Immunological response to acute infection, focusing on initial innate host response and its associations to inflammatory enhancement, genetic factors and clinical course.
Time frame
20303
Long term outcome
prevalence and risk factors of long-lasting complication, in particular the development of post-infectious chronic fatigue
Time frame
2030Locations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
Akershus universistetssykehusRecruiting Lørenskog
Norway
NorwaySponsors and contacts
Click on the lead sponsor to view all of their trials.
University Hospital, Akershus
Lead sponsor
St. Olavs Hospital
Collaborator
Helse Stavanger HF
Collaborator
Haukeland University Hospital
Collaborator
University Hospital of North Norway
Collaborator
Alesund Hospital
Collaborator
Norwegian Institute of Public Health
Collaborator
The University of New South Wales
Collaborator
University of Bristol
Collaborator
Sykehuset Ostfold
Collaborator
Nordlandssykehuset HF
Collaborator
Vestre Viken Hospital Trust
Collaborator
Helse Fonna
Collaborator
Helse Nord-Trøndelag HF
Collaborator
Oslo University Hospital
Collaborator
Sykehuset Innlandet HF
Collaborator
Source ClinicalTrials.gov